MedTrace Logo

C-Cog in Early Course Schizophrenia Study

NCT05662306 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-02-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.

Conditions

Interventions

DRUG

Aripiprazole Lauroxil

1064 mg 2-month long-acting injectable administered as an intramuscular injection over a 12-month period.

BEHAVIORAL

Computerized cognitive and functional skills training

Self-administered cognitive and technology focused skills training, administered at home for 2 hours per week for the first 12 weeks of the 12-month study period.

Sponsors & Collaborators

  • Alkermes, Inc.

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Dante Durand, MD · University of Miami Miller School

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2025-03-03
Completion
2025-03-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662306 on ClinicalTrials.gov